UNIVERSITY COLLEGE LONDON

Researchers at University College London have successfully treated Huntington's disease for the first time using gene therapy AMT-130, achieving a 75% reduction in disease progression after three years.

Eisai's investigational anti-MTBR tau antibody etalanetug (E2814) has been granted FDA Fast Track designation to expedite development for Alzheimer's disease treatment.

The PRIME trial demonstrated that biparametric MRI was noninferior to multiparametric MRI in detecting clinically significant prostate cancer, with detection rates of 29.2% versus 29.6% respectively.

A large UK retrospective study of 624,308 adults found that metformin initiated within 90 days of COVID-19 infection reduced Long COVID risk by 64% in overweight or obese individuals.

Upperton Pharma Solutions has secured funding from the VaxHub Sustainable Platform Funding Call to develop an oral formulation for adenovirus-vectored vaccines in collaboration with the University of Oxford.

Qualigen Therapeutics has been granted new patents covering QN-302, a cancer drug candidate targeting pancreatic and gastrointestinal cancers, across more than 25 countries including over 20 European nations, India, China, and Russia.

AstraZeneca's CARES Phase III clinical programme evaluating anselamimab in patients with Mayo stages IIIa and IIIb light chain amyloidosis did not achieve statistical significance for the primary endpoint of time to all-cause mortality and cardiovascular hospitalizations.

The phase 3b ProvIDHe study demonstrated that ivosidenib achieved a median progression-free survival of 4.7 months and overall survival of 15.5 months in patients with IDH1-mutated cholangiocarcinoma.

Skyhawk Therapeutics has dosed the first patient in its Phase 2/3 FALCON-HD trial evaluating SKY-0515, an oral RNA splicing modulator for Huntington's disease treatment.

The 2025 European Hematology Association Congress featured promising clinical trial results across multiple hematologic cancers, with novel trispecific and bispecific antibodies showing exceptional response rates in challenging patient populations.